InvestSMART

Biotron Limited (ASX: BIT) - Announcements

- Current share price for BIT : $0.002

ASX company news and announcements for Biotron Limited (BIT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Biotron Limited (BIT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Biotron Limited (BIT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Biotron Limited (BIT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$6 ANTIVIRAL ACTIVITY ENHANCED IN HIV/HCV GENOTYPE 3 PATIENTS 25 Oct 2013 10:22AM $0.090 $0.002 fallen by 97.78%
$6 Appendix 4C - quarterly 21 Oct 2013 12:44PM $0.097 $0.002 fallen by 97.94%
$6 Annual Report to shareholders 28 Aug 2013 5:02PM $0.110 $0.002 fallen by 98.18%
$6 BIT225 Capsule Formulation Trial Completed 14 Aug 2013 10:21AM $0.088 $0.002 fallen by 97.73%
$6 Patient Enrolment in Phase 2 Co-Infected Study Completed 31 Jul 2013 9:34AM $0.083 $0.002 fallen by 97.59%
$6 Appendix 4C - quarterly 26 Jul 2013 10:52AM $0.083 $0.002 fallen by 97.59%
$6 Presentation of HIV Trial Data to International AIDS Society 1 Jul 2013 9:48AM $0.082 $0.002 fallen by 97.56%
$6 R&D Tax Incentive Refund 31 May 2013 10:16AM $0.095 $0.002 fallen by 97.89%
$6 Appendix 4C - quarterly 30 Apr 2013 1:35PM $0.096 $0.002 fallen by 97.92%
$6 HIV TRIAL VALIDATES NOVEL DRUG MECHANISM 19 Mar 2013 9:45AM $0.115 $0.002 fallen by 98.26%
$6 Half Yearly Report and Accounts 27 Feb 2013 4:52PM $0.125 $0.002 fallen by 98.40%
$6 Appendix 4C - quarterly 17 Jan 2013 4:04PM $0.120 $0.002 fallen by 98.33%
$6 Biotron Completes Clinical Stage of HIV Clinical Trial 14 Dec 2012 11:31AM $0.120 $0.002 fallen by 98.33%
$6 Commencement of Three-Month Toxicology Studies For BIT225 27 Nov 2012 11:22AM $0.115 $0.002 fallen by 98.26%
$6 Presentation of BIT225 HCV 48-week data at AASLD Conference 16 Nov 2012 12:43PM $0.130 $0.002 fallen by 98.46%
$6 Key Phase 2 HIV/HCV Trial Commenced 9 Nov 2012 10:51AM $0.135 $0.002 fallen by 98.52%
$6 Appendix 4C - quarterly 22 Oct 2012 11:26AM $0.130 $0.002 fallen by 98.46%
$6 Biotron to Present Positive 48 Week Data from HCV Trial 16 Oct 2012 9:06AM $0.145 $0.002 fallen by 98.62%
$6 App 4E / Full Year Statutory Accounts 31 Aug 2012 11:24AM $0.089 $0.002 fallen by 97.75%
$6 Appendix 4C - quarterly 20 Apr 2012 3:40PM $0.140 $0.002 fallen by 98.57%
$6 Half Yearly Report and Accounts 28 Feb 2012 10:19AM $0.145 $0.002 fallen by 98.62%
$6 Appendix 4C - quarterly 24 Jan 2012 10:05AM $0.150 $0.002 fallen by 98.67%
$6 ASX price query and response 16 Jan 2012 9:54AM $0.170 $0.002 fallen by 98.82%
$6 Exercise of Options Raises $8.0 Million 6 Jan 2012 11:13AM $0.125 $0.002 fallen by 98.40%
$6 POSITIVE 3 MONTH DATA FOR BIT225 - 87% VIRUS FREE 7 Dec 2011 9:58AM $0.130 $0.002 fallen by 98.46%

476 - 500 of 594 results

Page 20 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.